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Summary 
Objectives: We aimed to evaluate acute hemodynamic effects and safety of 
landiolol in patients with acute coronary syndrome (ACS) treated with 
percutaneous coronary intervention (PCI).  
Background: Beta-blockers have been proven to be effective for the 
treatment of ischemic heart disease in both the acute and chronic phases. 
Landiolol, an ultra-short-acting and highly cardioselective beta-1 blocker, 
has become available in Japan. In the clinical setting, the hemodynamic 
response to landiolol administration remains unclear in patients presenting 
with ACS. 
Methods: From August 2007 to April 2008, landiolol was administered 
intravenously immediately before reperfusion procedure in 22 consecutive 
ACS patients (mean age, 63 ± 9 years; 15 men) with a heart rate (HR) of ≥70 
beats/min. The initial intravenous administration dose of landiolol was 20 
μg/kg/min in all patients. The maintenance dose was titrated with the aim of 
reducing HR by 15%. Acute hemodynamic data including HR and systolic 
and diastolic blood pressure were serially evaluated.  
Results: HR dropped significantly (from 87 ± 11 to 72 ± 8 beats/min, P<0.001) 
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20 minutes after landiolol initiation. However, systolic and diastolic pressure 
remained unchanged during administration of landiolol. Although landiolol 
was discontinued in 2 patients because of sinus bradycardia, no serious 
complications such as advanced degree atrioventricular block, requiring 
temporary cardiac pacing, severe hypotension, cardiogenic shock, or 
deterioration of heart failure were observed in the patients receiving 
landiolol.  
Conclusions: Landiolol was safe and effective in reducing oxygen demand of 
the ischemic heart by reducing only HR without lowering blood pressure in 
patients with ACS undergoing PCI. 
 
Key Words: landiolol; beta-blocker; acute coronary syndrome; acute 
hemodynamic response 
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INTRODUCTION 
Beta-blockers can reduce oxygen consumption in ischemic myocardium 
[1], and they have been proven to be effective for the management of ischemic 
heart disease in both the acute and chronic phases [2-6]. However, 
intravenous propranolol, not usually given as a continuous infusion, has 
limited safety because it lacks cardioselectivity, and its effects continue long 
after treatment has stopped. Landiolol hydrochloride (ONOACT™; Ono 
Pharmaceutical, Osaka, Japan) is an ultra-short-acting, selective beta-1 
blocker that is now commercially available in Japan. This agent has an 
extremely short elimination half-time of 4 minutes [7] and might allow easy 
titration during the acute phase of acute coronary syndrome (ACS). Previous 
studies reported the effectiveness and safety of landiolol administration in 
patients who developed tachyarrhythmia in the perioperative phase [8-14]. 
However, cardioprotective effects of landiolol against myocardial ischemic 
injury have not been investigated. In the setting of ACS including 
myocardial infarction, the hemodynamic response to landiolol 
administration remains unclear. In this preliminary study, we aimed to 
evaluate the acute hemodynamic effects and safety of landiolol in patients 
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with ACS undergoing percutaneous coronary intervention (PCI). 
 
METHODS 
Study Population 
We conducted a preliminary study of investigating the acute 
hemodynamic effects of landiolol in patients with ACS. From August 2007 to 
April 2008, a total of 97 patients with ACS were treated with PCI at our 
institution. Among them, eligible subjects included 22 consecutive patients 
with a heart rate of ≥70 beats/min (mean age, 62 ± 9 years; 15 men) who were 
administered landiolol intravenously. ACS was defined as prolonged chest 
pain (≥10min) with ST segment elevation or depression (≥0.05mV) in 2 or 
more contiguous leads on the electrocardiogram and significant coronary 
artery stenosis or occlusion on the coronary angiogram. Exclusion criteria 
included development of cardiogenic shock, bradycardia, atrioventricular 
block, heart failure of Killip class III or IV, hypotension, and a history of 
bronchial asthma. Patients who previously had been on oral beta-blockers 
were also excluded. The study was approved by the ethics committees of our 
institute. 
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Interventional Procedure 
Prior to the interventional procedure, unfractionated heparin was 
administered to maintain an activated clotting time of ≥300 seconds. 
Experienced interventional cardiologists performed PCI through the femoral 
or radial approach with 6 French catheters. Dual antiplatelet agents were 
prescribed to the patients undergoing coronary artery stenting, i.e. aspirin 
200 mg daily and clopidogrel 75 mg daily, following a 300 mg loading dose of 
clopidogrel. A glycoprotein IIb/IIIa receptor antagonist was not available in 
Japan at the time of the study. The contrast agent used was iopamidol 370 
mg I/ml (Schering AG, Berlin, Germany). Written informed consent was 
obtained from all patients before undergoing PCI. 
Treatment with Landiolol 
Landiolol was initiated immediately before the reperfusion procedure. 
The endpoint of treatment was a 15% reduction in heart rate. Drug 
administration consisted of initial titration followed by maintenance infusion. 
The initial intravenous administration dose of landiolol was determined to 
be 20 μg/kg/min for 5 minutes in all patients on the basis of our institution’s 
protocol. At the end of 5 minutes, the patient’s vital signs were recorded, and 
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if they had not met the study endpoint, landiolol was increased by 5 to 10 
μg/kg/min every 1 minute. If the patient achieved a 15% reduction in heart 
rate, a maintenance dose of landiolol was titrated. If the decrease in heart 
rate was inadequate during this period, the landiolol dose could be increased 
up to a maximum of 40 μg/kg/min. The maintenance dose could also be 
adjusted downward if necessary. After completion of the PCI, landiolol was 
discontinued and followed by oral beta-blocker treatment. 
Hemodynamic Evaluation 
Hemodynamic data, including heart rate and systolic and diastolic blood 
pressure, were recorded at baseline and 1, 2, 5, 10, and 20 minutes after 
initiation of landiolol. Heart rate was serially recorded by 
electrocardiographic heart rate monitor and arterial blood pressure was 
measured invasively through the arterial catheter. Hemodynamic effects 
were assessed up to 20 minutes after landiolol initiation because of its very 
short 4-minute half-life in blood. 
Blood Sampling and Left Ventricular Function 
We drew blood samples to measure serum concentration of creatine 
phosphokinase (CPK) and the MB isoenzyme of CPK (CPK-MB) before the 
9 
 
procedure and at 6, 12, and 24 hours after PCI. Left ventricular function was 
assessed by transthoracic echocardiogram at 5 days after PCI. 
Statistical Analysis 
Continuous variables are expressed as means ± SD. The Student t-test 
was used to assess the differences between continuous variables. Categorical 
variables are reported as observed number of patients (percentages) and 
were analyzed by either chi-square or Fisher exact test, as appropriate. A 
repeated measure ANOVA was performed to examine the differences in the 
time course changes in variables, and post hoc analysis was employed with  
the Scheffe’s test. Pearson’s correlation coefficient was used to assess the 
relation between continuous variables. A two-sided P value of <0.05 was 
considered significant throughout the analysis. Data were analyzed with 
SPSS Statistics 19.0 for Windows (IBM SPSS Statistics Inc., Chicago, IL, 
USA). 
 
RESULTS 
Patient Characteristics 
Baseline patient characteristics are shown in Table 1. Landiolol was 
10 
 
administered intravenously in 13 patients presenting with acute myocardial 
infarction and 9 patients with unstable angina. The left anterior descending 
artery was involved most frequently. 
Hemodynamic Data 
Hemodynamic data at baseline are shown in Table 2. Figure 1.A shows a 
statistically significant reduction in heart rate after initiation of landiolol, 
from 87 ± 11 beats/min at baseline to 72 ± 8 beats/min after 20 minutes 
[F(5,170) = 25.8, P<0.001]. The average decrease in heart rate was 15 
beats/min at 20 minutes after administration of landiolol. The reduction in 
heart rate correlated with baseline heart rate (r = 0.687, P<0.001, Figure 2). 
In contrast, as shown in Figure 1.B, both systolic and diastolic blood 
pressure remained unchanged during landiolol infusion [F(5,170) = 1.75, P = 
0.13, and F(5,170) = 0.84, P = 0.53, for systolic and diastolic blood pressure, 
respectively]. 
Titration of Landiolol 
The initial intravenously administered dose of landiolol was 20 
μg/kg/min in all patients. This same dose was maintained in 13 (59%) 
patients. According to the change in heart rate, the maintenance dose was 
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decreased to 10 μg/kg/min in 7 (32%) patients, whereas 2 (9%) patients 
required a higher dose. The mean dose of landiolol was 17.8 ± 6.0 μg/kg/min 
when the appropriate heart rate was obtained. The mean duration of 
landiolol administration was 44 ± 14 minutes (median, 45 minutes; inter 
quartile range, 38-52 minutes), and 21 (95%) patients received subsequent 
oral beta-blocker treatment: 11 patients were on carvedilol, 7 patients on 
metoprolol, and 3 patients on bisoprolol. A representative case of landiolol 
administration is shown in Figure 3. 
Adverse Effects 
Landiolol was discontinued prematurely in 2 patients with AMI because 
of a bradycardic response, which recovered immediately without inserting 
temporary cardiac pacing. The culprit arteries were the right coronary artery 
in 1 patient and the left circumflex in the other. In the latter, the left 
circumflex was the dominant coronary artery with hypoplastic right coronary 
artery. However, no serious adverse effects such as an advanced degree of 
atrioventricular block, requiring temporary cardiac pacing, severe 
hypotension, cardiogenic shock, or deterioration of heart failure were 
observed. None of the patients who were administered landiolol 
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intravenously died during hospitalization. 
 
DISCUSSION 
The main findings of this study were that landiolol could decrease heart 
rate rapidly without lowering blood pressure in patients presenting with 
ACS, and a positive correlation between baseline heart rate and the 
reduction in heart rate was observed. In addition, landiolol could be used 
safely without hemodynamic complications approximately in 90% of the 
selected ACS patients. 
Landiolol hydrochloride, which has a pharmacological resemblance to 
esmolol, is now commercially available in Japan as an ultra-short-acting 
agent with high beta-1 receptor selectivity. Landiolol has much higher 
cardioselectivity than that of esmolol (ratio of beta-1/beta-2 selectivity: 
landiolol, 255; esmolol, 33) and is also shorter acting than esmolol 
(elimination half-time: landiolol, 4 minutes; esmolol, 9 minutes) [7, 15]. In 
animal experiments, landiolol had less effect on blood pressure than did 
esmolol [16]. This favorable property allows easy titration and results in 
fewer side-effects than with other long-acting beta-1 blockers and is 
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considered to be a suitable hemodynamic response for ischemic myocardium 
in the acute phase. 
Hemodynamic responses to landiolol administration in patients with 
ACS have not been investigated in the clinical setting, and the effectiveness 
and safety of landiolol remain unclear. To our knowledge, this is the first 
report to investigate the acute hemodynamic effects of landiolol in patients 
with ACS. The present study showed that landiolol rapidly attenuated the 
heart rate without lowering the blood pressure. The average of decrease in 
heart rate was 15 beats/min after 20-minute administration of landiolol, and 
a positive correlation between baseline and the reduction in heart rate was 
observed. Previous studies showed a consistent hemodynamic response with 
landiolol, and the safety and effectiveness of this agent have been shown in 
patients with tachyarrhythmia in the perioperative setting and in the 
intensive care unit [8-10, 13, 17]. We propose that landiolol administration 
would be taken into consideration to the ACS patients concomitant with high 
heart rate, in whom an attenuation of heart rate by using landiolol might 
allow decreasing oxygen consumption. The temporary cardiac pacing would 
not be essential when using landiolol because of its short elimination half 
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time. However, the AMI patient involving right coronary artery might be 
inserted temporary cardiac pacing prior to landiolol administration because 
of a possibility of bradycardiac response. In this study, 4 patients with Killip 
class of II were administered landiolol safely without deterioration of heart 
failure, however, the patients with Killip class of III and IV were excluded 
from this study. 
The regimen recommended on the landiolol package insert in Japan is a 
loading dose of 125 μg/kg/min, followed by a maintenance dose of 10-40 
μg/kg/min. In all patients in the present study, we initiated landiolol at dose 
of 20 μg/kg/min without first infusing a loading dose. The ultra-short-acting 
and 4-minute elimination half time of landiolol allow easy and rapid titration 
of the maintenance dose. However, several reports indicated that a low dose 
of ≤5 μg/kg/min was effective for suppression of tachyarrhythmia or 
adjustment of heart rate [13, 14, 18]. In the real-world clinical setting, the 
optimal dose of landiolol for cardioprotection remains to be undetermined, 
and investigation is continuing. 
Several recent basic experiments showed that landiolol has 
cardioprotective effects against ischemia-reperfusion injury [19-21]. Landiolol 
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is speculated to have similar cardioprotective effects against myocardial 
ischemic injury in the human heart. Recently, the PASCAL trial for coronary 
artery bypass grafting had shown that landiolol decreased levels of 
postoperative cardiac enzymes including CPK-MB and troponin-I, as well as 
development of postoperative atrial fibrillation [18]. Because our study was of 
a single-arm observational design, further investigation will be required to 
determine whether landiolol has an effect on salvaging ischemic myocardium 
and improving prognosis in patients with ACS treated by PCI. 
 
LIMITATIONS 
The present study has several limitations. First, this study was of a 
single-arm observational design and was performed at a single center, and 
the sample size was small. Second, other hemodynamic parameters such as 
cardiac output, pulmonary artery pressure, and pulmonary capillary wedge 
pressure were not assessed because a pulmonary artery catheter was not 
inserted. Third, this study was limited to short-term hemodynamic response, 
and thus, there were no long-term data on whether prognostic benefit was 
obtained. 
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CONCLUSIONS 
Landiolol was safe and effective in rapidly reducing heart rate by 
reducing only heart rate without lowering the blood pressure in patients 
with ACS undergoing PCI. These effects of landiolol are considered to be a 
favorable hemodynamic response in patients with ischemic myocardium in 
the acute phase. 
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Figure legend 
 
Fig.1.A: A repeated measure ANOVA showed a significant attenuation in 
serial change of heart rate after administration of landiolol [F(5,170) = 25.8, 
P<0.001]. Graph data are presented as mean ± SD. Asterisk (*) indicates 
significant difference in heart rate (P<0.001) between baseline and each time 
point as determined by repeated ANOVA followed by Scheffe’s post hoc test. 
 
Fig.1.B: Serial changes in systolic and diastolic blood pressure were shown. 
There were no significant differences in serial change of either systolic or 
diastolic blood pressure as determined by repeated measure ANOVA. Graph 
data are presented as mean ± SD. Black diamond indicates systolic blood 
pressure, and white triangle does diastolic blood pressure. SBP, systolic 
blood pressure; DBP, diastolic blood pressure. 
 
Fig.2: Reduction in heart rate correlated significantly with baseline heart 
rate. 
 
Fig.3: A representative case is shown of a 66-year-old woman who presented 
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to the emergency room complaining of chest discomfort. An 
electrocardiogram showed ST-segment depression (A, left panel), suggesting 
unstable angina, and the patient was referred to the cath lab. Coronary 
angiogram showed significant stenosis in the left anterior descending artery 
(B, left panel). Intravenous administration of landiolol at a dose of 20 
μg/kg/min was initiated, resulting in immediate improvement of myocardial 
ischemia (A, right panel and C). Subsequently, a Taxus-Liberte™ stent was 
successfully implanted in the left anterior descending artery (B, right panel). 
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Table 1. Baseline Patient Characteristics 
 
Characteristics N = 22 
Age (years) 63 ± 9 
Male sex, n (%) 15 (68%) 
Risk factors, n (%) 
 Hypertension 
 Dyslipidemia 
 Diabetes 
Smoking 
 
16 (73%) 
11 (50%) 
 9 (41%) 
13 (59%) 
Killip class, n (I/II/III/IV) 18/4/0/0 
ECG on presentation, n (%) 
  Sinus rhythm 
  Ventricular arrhythmia 
 
22 (96%) 
1 (4%) 
Diagnosis at presentation, n (%) 
Acute myocardial infarction 
Unstable angina 
 
13 (59%) 
 9 (41%) 
Culprit artery, n (%) 
  Left anterior descending 
  Left circumflex 
Right coronary 
 
16 (73%) 
 5 (23%) 
 1 (4%) 
Time from symptom onset to reperfusion, (min) 367 ± 301 
 
Data are presented as absolute value (percentage) or mean ± SD. 
ECG, electrocardiogram. 
Table 2. Hemodynamic and Cardiac Enzyme Data 
 
Characteristics 
 
Hemodynamic data at baseline 
  Systolic blood pressure (mmHg) 
  Diastolic blood pressure (mmHg) 
  Heart rate (beats/min) 
 
133 ± 22 
76 ± 18 
87 ± 11 
Cardiac enzymes, AMI only 
Peak CPK, U/L 
Peak CPK-MB, U/L 
 
2900 ± 2234 
301 ± 236 
LVEF 
All patients, % 
AMI patients, % 
 
55 ± 10 
49 ± 7 
 
Data are presented as mean ± SD. AMI,acute myocardial infarction; CPK, creatine 
phosphokinase; LVEF, left ventricular ejection fraction. 
 
